Exploratory/Developmental Grants Related to the World Trade Center Health Program (R21)
This grant funds early-stage research to improve diagnosis or treatment for those monitored or treated under the World Trade Center Health Program, focusing on new or untested approaches.
Funder: Centers for Disease Control and Prevention - ERA
Due Dates: May 29, 2026 (Letter of intent) | June 23, 2026 (Full application) | November 6, 2026 (Letter of intent) | December 8, 2026 (Full application) | September 24, 2027 (Letter of intent) | October 26, 2027 (Full application)
Funding Amounts: Up to $365,000 per year (max $500,000 total over 2 years); typical awards average $250,000/year; total program funding approx. $18M over 3 years.
Summary: Supports exploratory/developmental research to improve diagnosis, treatment, and well-being for populations exposed to the September 11, 2001 attacks through the World Trade Center Health Program.
Key Information: Non-U.S. entities and foreign components are not eligible to apply.
Description
This grant supports early-stage, exploratory, or developmental research projects (R21 mechanism) that seek to advance scientific knowledge, diagnosis, treatment, and overall well-being of individuals exposed to the September 11, 2001 terrorist attacks. The focus is on projects with limited preliminary data that have the potential to improve care for World Trade Center (WTC) Health Program members, including FDNY responders, general responders, certified-eligible survivors, and other less-exposed populations. Research may address diagnostic or treatment uncertainty, explore new interventions or methodologies, and expand understanding of 9/11-related health conditions.
